OmniAb (OABI) Non-Current Assets (2021 - 2026)
OmniAb (OABI) reported Non-Current Assets of $228.5 million for Q1 2026, down 9.53% year-over-year from $252.6 million in Q1 2025, and down 2.99% quarter-over-quarter from $235.6 million in Q4 2025.
OmniAb (OABI) Non-Current Assets (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Non-Current Assets data on file, last reported at $228.5 million in Q1 2026.
- Non-Current Assets for Q1 2026 came in at $228.5 million, down 9.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $955.5 million (down 8.56% YoY), and the FY2025 annual result was $235.6 million, down 8.49% from the prior year.
- Non-Current Assets slipped to $228.5 million in Q1 2026 per OABI's latest filing, from $235.6 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $296.3 million in Q4 2022 and troughed at $228.5 million in Q1 2026.
- A 5-year average of $260.5 million and a median of $257.4 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2026: Non-Current Assets grew 23.82% in 2023, then dropped 9.53% in 2026.
- A 5-year view of Non-Current Assets shows it stood at $296.3 million in 2022, then decreased by 5.38% to $280.3 million in 2023, then slipped by 8.17% to $257.4 million in 2024, then dropped by 8.49% to $235.6 million in 2025, then decreased by 2.99% to $228.5 million in 2026.
- Business Quant data shows OABI's Non-Current Assets at $228.5 million in Q1 2026, $235.6 million in Q4 2025, and $243.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 62,953.78 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 486.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.18 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 39.71 Mn |
| 10 | OmniAb | 294.96 Mn | 252.00 Mn | 14.41 Mn | 228.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 228.53 Mn |
| Dec 31, 2025 | 235.57 Mn |
| Sep 30, 2025 | 243.34 Mn |
| Jun 30, 2025 | 248.06 Mn |
| Mar 31, 2025 | 252.60 Mn |
| Dec 31, 2024 | 257.42 Mn |
| Sep 30, 2024 | 264.95 Mn |
| Jun 30, 2024 | 269.96 Mn |
| Mar 31, 2024 | 275.84 Mn |
| Dec 31, 2023 | 280.32 Mn |
| Sep 30, 2023 | 284.86 Mn |
| Jun 30, 2023 | 289.30 Mn |
| Mar 31, 2023 | 291.96 Mn |
| Dec 31, 2022 | 296.26 Mn |
| Sep 30, 2022 | 237.19 Mn |
| Jun 30, 2022 | 236.10 Mn |
| Mar 31, 2022 | 235.80 Mn |
| Dec 31, 2021 | 281.92 Mn |
| Sep 30, 2021 | 235.75 Mn |